Personalized immunotherapy against several neuronal and brain tumors

Patent metadata

Field	Value
Publication number	US-11529400-B1
Application number	US-202217852206-A
Country	US
Kind code	B1
Filing date	Jun 28, 2022
Priority date	Nov 4, 2013
Publication date	Dec 20, 2022
Grant date	Dec 20, 2022

Abstract

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

First claim

The invention claimed is:

1. A method of treating a patient who has brain cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence of QYVFIHDTL (SEQ ID NO: 89).

2. The method of claim 1 , further comprising administering to said patient an adjuvant selected from anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.

3. The method of claim 1 , wherein the activated T cells are cytotoxic T cells produced by contacting T cells with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell.

4. The method of claim 2 , wherein the adjuvant is IL-1.

5. The method of claim 2 , wherein the adjuvant is IL-2.

6. The method of claim 2 , wherein the adjuvant is IL-7.

7. The method of claim 2 , wherein the adjuvant is IL-12.

8. The method of claim 2 , wherein the adjuvant is IL-13.

9. The method of claim 2 , wherein the adjuvant is IL-15.

10. The method of claim 2 , wherein the adjuvant is IL-21.

11. A method of eliciting an immune response in a patient who has brain cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence of QYVFIHDTL (SEQ ID NO: 89).

12. The method of claim 11 , further comprising administering to said patient an adjuvant selected from anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.

13. The method of claim 11 , wherein the activated T cells are cytotoxic T cells produced by contacting T cells with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell.

14. The method of claim 12 , wherein the adjuvant is IL-1.

15. The method of claim 12 , wherein the adjuvant is IL-2.

16. The method of claim 12 , wherein the adjuvant is IL-7.

17. The method of claim 12 , wherein the adjuvant is IL-12.

18. The method of claim 12 , wherein the adjuvant is IL-13.

19. The method of claim 12 , wherein the adjuvant is IL-15.

20. The method of claim 12 , wherein the adjuvant is IL-21.

Assignees

• Immatics Biotechnologies Gmbh

Inventors

• Kuttruff-Coqui Sabrina
• Weinschenk Toni
• Fritsche Jens
• Walter Steffen
• Hilf Norbert
• Schoor Oliver
• Song Colette
• Singh Harpreet

Classifications

• C07K7/08

  having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title

• C07K7/06 Primary

  having 5 to 11 amino acids · CPC title

• C07K14/47

  from mammals · CPC title

• C07K14/70539

  MHC-molecules, e.g. HLA-molecules · CPC title

• A61K2039/80

  Vaccine for a specifically defined cancer · CPC title